Has your company recently designed, built or renovated a state-of-the-art pharmaceutical or biotechnology facility that is best in its class? Submit an entry into the 2020 ISPE Facility of the Year Awards (FOYA) Program, and your facility may win the coveted Facility of the Year Award.
ISPE’s Facility of the Year Awards Program is the premier global awards program recognizing innovation and creativity in the pharmaceutical and biotechnology manufacturing industries. The Facility of the Year Awards program showcases accomplishments in facility design, construction, and operation. It celebrates the shared commitment and dedication of individuals working for different companies worldwide to enhance patient health and safety through innovation and advancements in pharmaceutical manufacturing technology.
Projects selected for these prestigious awards set the standard for pharmaceutical facilities by demonstrating excellence in the categories of:
The full submission should be prepared in accordance with the guidelines provided in these instructions and submitted electronically. See pages 7–9 for detailed submission instructions and recommendations for electronic submission. Submissions must be received by the stated deadline and each submission must include all required information, signatures, and payment in order to be complete.
Payment for the entry fee in the amount of US$495 must accompany each submission.
Please send completed forms to Barbara Peck, Manager, Community and Industry Recognition at firstname.lastname@example.org. Final project submissions are due no later than 22 November 2019. For more information about completing your final submission, please read the Program Guide portion of the 2020 Program Guide and Submission Instructions.
Projects submitted from many countries around the world have been named Category Award Winners in the annual Facility of the Year Awards Program, and we'd love to receive a submission from you.
GMP Manufacturing-Based Projects
GMP manufacturing-based projects consisting of buildings, equipment, systems, and manufacturing methodologies deployed to manufacture regulated pharmaceutical drug substances, drug products, medical devices, combination products, and other commercial entities under the purview of the US FDA, and other global regulatory bodies.
In addition, non-regulated facilities that meet the criteria listed above may also be eligible if demonstration is provided to indicate they are operated within similar GMP guidelines.
GMP and Non-GMP Process Development Projects
Project examples may include laboratories, pilot plants, medical device production, fill/finish, packaging facilities, and other similar process development facilities that may or may not be regulated. Submissions will be primarily judged on the merits of the applied innovation as it pertains to the development of pharmaceutical and biotechnology products.
Facilities must have completed construction and major systems validation between 1 November 2017 and 30 November 2019. As an example, the facility should be occupied and in full operation; or capable of producing product in accordance with an approved product license or under similar operational guidelines.
For GMP regulated facilities, the facility should have been granted an operating license by an appropriate health authority, or be awaiting such approval based on an application that has already been made by 30 November 2019.